Provided by Tiger Trade Technology Pte. Ltd.

CMS

11.570
-0.290-2.45%
Volume:6.11M
Turnover:70.59M
Market Cap:28.15B
PE:16.11
High:12.130
Open:11.920
Low:11.420
Close:11.860
52wk High:15.449
52wk Low:9.510
Shares:2.43B
HK Float Shares:2.43B
Volume Ratio:0.62
T/O Rate:0.25%
Dividend:0.33
Dividend Rate:2.82%
EPS(LYR):0.718
ROE:8.42%
ROA:5.62%
PB:1.34
PE(LYR):16.11
PS:2.77

Loading ...

CMS Reports 2025 Financial Results: Profit Attributable to Owners Declines 8.08% to Approximately 1.489 Billion Yuan

Stock News
·
Mar 16

China Medical System FY2025 profit fell 10.5% to RMB1.44 billion as turnover rose 9.9% to RMB8.21 billion

Reuters
·
Mar 16

China Medical System Holdings - Profit for Year RMB1,443.3 Mln

THOMSON REUTERS
·
Mar 16

China Medical System Holdings - Proposed Final Dividend of RMB0.1366 per Share

THOMSON REUTERS
·
Mar 16

Assessing China Medical System (SEHK:867) Valuation After A Recent Share Price Pullback

Simply Wall St.
·
Mar 14

China Medical System Holdings - Nmpa Approves Desidustat Tablets for Renal Anaemia in China

THOMSON REUTERS
·
Mar 13

China Medical System Gets China Nod to Market Renal Anaemia Drug

MT Newswires
·
Mar 13

CMS Gains Chinese Approval for New Anemia Drug Desidustat

Stock News
·
Mar 13

China Medical System Holdings - New Drug for Renal Anaemia Desidustat Tablets Approved for Marketing by China Nmpa

THOMSON REUTERS
·
Mar 13

China Medical System says China approves Desidustat tablets for CKD anaemia

Reuters
·
Mar 13

CMS Subsidiary Dermavon Records First China Prescriptions for Lumirix Vitiligo Cream

Reuters
·
Mar 13

CMS Secures Regulatory Clearance for Clinical Trials of INHBE Small RNA Drug CMS-D008 Targeting Overweight and Obesity

Deep News
·
Mar 06

China Medical System Holdings Limited Approval of Drug Clinical Trials for Overweight/Obesity Indication of Self-Developed Drug CMS-D008

THOMSON REUTERS
·
Mar 04

CMS (00867) Schedules Board Meeting for 16 March 2026 to Review 2025 Annual Results

Bulletin Express
·
Mar 04

CMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity

Bulletin Express
·
Mar 04

CMS Pharmaceutical's Innovative siRNA Drug CMS-D008 Receives Clinical Trial Approval for Overweight/Obesity Indication

Stock News
·
Mar 04

China Medical System Holdings - CMS-D008 Receives Drug Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
Mar 04

China Medical System Holdings wins NMPA approval to start CMS-D008 obesity clinical trials

Reuters
·
Mar 04

China Medical System (00867) Releases February 2026 Monthly Return

Bulletin Express
·
Mar 02

CMS Receives Initial "Buy" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth

Stock News
·
Feb 25